Can you provide information on the etiology, clinical presentation, management, and prevention of hand‑foot‑and‑mouth disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Hand, Foot, and Mouth Disease: Clinical Overview

Hand, foot, and mouth disease (HFMD) is a common, typically self-limiting viral illness primarily affecting children under 5 years, caused mainly by enteroviruses (particularly Coxsackievirus A16 and Enterovirus A71), presenting with fever, painful oral ulcers, and characteristic vesicular rash on hands and feet.

Etiology

HFMD is caused by enteroviruses within the Picornaviridae family 1. The primary causative agents are:

  • Coxsackievirus A16 (CV-A16) - most common cause of typical mild disease
  • Enterovirus A71 (EV-A71) - associated with more severe disease and higher complication rates 2
  • Coxsackievirus A6 (CV-A6) - increasingly recognized as a major etiologic agent, accounting for 86.2% of RT-PCR positive cases in recent studies 3

EV-A71 infections carry significantly higher risk of severe complications including encephalitis, brainstem damage, neurogenic pulmonary edema, and myocardial impairment leading to circulatory failure 2.

Clinical Presentation

Typical Features

The classic presentation includes 4, 3:

  • Fever: Present in 100% of cases; high-grade (≥101.3°F) in 66.7%, low-grade in 33.3%
  • Oral lesions: Painful oral ulcerations (80.5% painful, 19.5% painless) affecting buccal mucosa, tongue, and palate
  • Rash distribution:
    • Hands: 100%
    • Feet: 90.8%
    • Knees: 82.8%
    • Buttocks: 79.3%
  • Rash characteristics: Painful (74.7%) and/or itchy (73.6%); maculopapular or papulovesicular

Atypical Presentations

  • Adults: Increasingly recognized with more severe, generalized vesiculopapular eruptions involving trunk and groin 5
  • CV-A6 infections: Associated with onychomadesis (nail shedding) occurring weeks after initial infection 1

Severe Complications

Critical warning signs requiring immediate attention 2:

  • Neurological: Meningitis, encephalitis, acute flaccid myelitis/paralysis
  • Cardiopulmonary: Myocarditis, neurogenic pulmonary edema
  • Systemic: Sepsis-like syndrome

Diagnosis

Clinical Diagnosis

Diagnosis is primarily clinical based on the characteristic triad of fever, oral ulcers, and acral rash 4, 6.

Laboratory Testing

When laboratory confirmation is needed (atypical presentations, severe cases, outbreak investigation) 1:

Recommended specimen collection by presentation:

Clinical Scenario Primary Specimens Additional Specimens
Typical HFMD Vesicle fluid, throat swab Stool
Meningitis/Encephalitis CSF, stool Respiratory sample, blood
Acute flaccid myelitis Respiratory sample, stool CSF, blood
Severe/complicated Multiple sites Blood (before IVIG)

Diagnostic methods:

  • RT-PCR targeting 5' non-coding region: Gold standard for detection due to sensitivity, specificity, and rapid turnaround 1
  • VP1 capsid protein gene sequencing: Required for viral typing (cannot rely on 5'NCR due to recombination) 1

Critical caveat: EV-D68 and EV-A71 may only be detectable in respiratory specimens, not CSF, in neurological cases 1. Immunocompromised patients can shed virus in stool for years 1.

Management

Supportive Care

Treatment is entirely supportive as no specific antiviral agents are currently approved 2, 4:

  • Pain management: Acetaminophen or ibuprofen
  • Hydration: Critical due to painful oral lesions limiting intake
  • Avoid oral lidocaine: Not recommended 4

Expected resolution timeline 3:

  • Fever: 5 days (58.6% of cases), up to 5-7 days (23%)
  • Rash: Within 7 days (68.8% of cases)
  • Oral ulcers: 5-7 days (51.8%), up to 5 days (24.1%)

Severe/Complicated Disease

For severe or complicated HFMD with neurological or cardiopulmonary involvement, intravenous immunoglobulin (IVIG) should be considered 2. This recommendation is supported by multiple national and international guideline committees.

Investigational agents (not yet approved) include ribavirin, suramin, mulberroside C, aminothiazole analogs, and sertraline 2.

Prevention

Personal Hygiene Measures

The most effective prevention strategies are handwashing and disinfection of contaminated surfaces and fomites 4:

  • Hand hygiene (particularly after diaper changes, before food preparation)
  • Breastfeeding in infants 7
  • Environmental sanitation
  • Avoiding contact with infected individuals

Transmission Routes

  • Fecal-oral
  • Oral-oral (respiratory droplets)
  • Direct contact with vesicle fluid 4

Peak transmission: Spring to fall in North America 4

Vaccination

Inactivated EV-A71 vaccines developed in China demonstrate >90% efficacy in preventing severe HFMD 7. These vaccines are currently used in China but not licensed for general use globally 6. Vaccination is recommended for susceptible individuals in high-risk endemic areas 2.

Key Clinical Pitfalls

  1. Do not dismiss HFMD in adults - atypical presentations are increasingly common and may be severe 5
  2. Always obtain respiratory specimens in neurological cases - EV-D68 and EV-A71 may not appear in CSF 1
  3. Collect baseline blood before IVIG administration in severe cases 1
  4. Monitor for delayed onychomadesis with CV-A6 infections 1
  5. Lower threshold for investigation in immunocompromised patients - presentations are non-specific and severe 1

Differential Diagnosis

Consider: erythema multiforme, herpes simplex, varicella, measles, and other viral exanthems 4.

References

2
Research

Hand, Foot, and Mouth Disease: A Narrative Review.

Recent advances in inflammation & allergy drug discovery, 2022

4
Research

Hand-Foot-and-Mouth Disease: Rapid Evidence Review.

American family physician, 2019

6
Research

Hand, Foot, and Mouth Disease Outbreak What You Need to Know.

Infectious disorders drug targets, 2023

Related Questions

What age groups are commonly affected by hand‑foot‑and‑mouth disease, and can an individual experience multiple episodes due to different viral strains?
In a 21-year-old male treated with amoxicillin and metronidazole for a dental infection who now has painful aphthous ulcers and new hand and foot lesions, could this represent hand‑foot‑mouth disease, what other conditions should be considered, and how should significant pain limiting oral intake be managed?
What is the appropriate management for diarrhea in a child with hand‑foot‑and‑mouth disease?
How should I manage an 8‑month‑old male infant (weight 6 kg) presenting with low‑grade fever (~100 °F) and oral ulcerations, given that his sister had hand‑foot‑mouth disease?
What is the appropriate management for hand, foot, and mouth disease?
Is there a required time gap between packed red blood cell (PRBC) transfusion and single‑donor plasma (SDP) transfusion?
What is the antibiotic of choice for a patient with end‑stage renal disease on hemodialysis presenting with acute diarrheal illness?
What is the appropriate amoxicillin dosage for an uncomplicated dental infection in a healthy adult?
What is a ganglion cyst?
In a patient with chronic obstructive pulmonary disease experiencing recurrent bronchospasm despite maximal inhaled therapy, what next steps in management are recommended?
Can azithromycin be used in a patient on hemodialysis who has acute diarrheal illness?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.